Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach.
Alessandro Di MinnoRoberta Clara OrsiniMattia ChiesaViviana CavalcaIlenia Lorenza CalcaterraMaria TripaldellaAndrea AnesiSusanna FiorelliSonia EliginiGualtiero Ivanoe ColomboElena TremoliBenedetta PorroMatteo Nicola Dario Di MinnoPublished in: Biomedicines (2021)
Taking advantage of untargeted metabolomics, we first provided evidence of concomitant reductions in inflammation and platelet activation metabolites in FH patients receiving a 12 week treatment with PCSK9i.